Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Yuhong Yan is active.

Publication


Featured researches published by Yuhong Yan.


Oncotarget | 2017

Role of an imbalanced miRNAs axis in pathogenesis of psoriasis: novel perspectives based on review of the literature

Mao-Jie Wang; Yong-Yue Xu; Run-Yue Huang; Xiu-Min Chen; Haiming Chen; Ling Han; Yuhong Yan; Chuanjian Lu

BACKGROUND Specific profile of microRNAs (miRNAs, miR) expressed in psoriasis has been identified in the past few years, while the studies on roles and molecular mechanisms of these miRNAs are still on the way. In our previous study, four specific miRNAs (miR-31, miR-203, hsa-miR-99a and miR-125b) were found to be specifically altered in psoriatic lesions.We therefore conducted a systematic literature review in this study to reveal the role of these miRNAs in the pathogenesis of psoriasis in order to inform future research. METHODS The related articles indexed in PubMed (MEDLINE) database were searched and analyzed. We identified eligible studies related to the mechanism research of miR-31, miR-203, hsa-miR-99a and miR-125b in psoriasis or psoriatic lesional skin from inception up to July 2016. The experts in the field of miRNAs and Psoriasis were involved in analysis process. RESULT Both miR-31 and miR-203 are dramatically upregulated in psoriatic lesions. The former plays the pro-proliferative, pro-differentiative and pro-inflammatory roles and the latter holds the potentials for anti-proliferation, pro-inflammation and pro-differentiation in psoriatic keratinocytes. Conversely, both hsa-miR-99a and miR-125b are significantly downregulated in psoriatic skin. These two miRNAs are able to inhibit proliferation while promote differentiation of psoriatic keratinocytes, and miR-125b can also suppress inflammation in psoriatic lesions. By analyzing the contexts related to these miRNAs, we found that each of them does not act alone but rather work in concert with other miRNAs. The imbalance between miR-31/miR-203and hsa-miR-99a/miR-125b may contribute to the intense proliferation and abnormal differentiation of psoriatic keratinocytes, which is a characteristic of pathogenesis of psoriasis. CONCLUSION An imbalanced miRNAs axis was for the first time outlined. Apparently, upregulation of miR-31/miR-203 and downregulation of hsa-miR-99a/miR-125b work together in concert to facilitate the development of psoriasis pathogenesis. Further work in this field holds the potentials to open a new way to study psoriasis.


Journal of The European Academy of Dermatology and Venereology | 2013

Psychometric properties of the Chinese version of Dermatology Life Quality Index (DLQI) in 851 Chinese patients with psoriasis.

Z. He; Chuanjian Lu; M.K.A. Basra; A. Ou; Yuhong Yan; L. Li

Background  The Dermatology Life Quality Index (DLQI) is one of the most frequently used scales to evaluate the impact of skin disease on patients’ quality of life (QoL). There has not been psychometric evaluation of the Chinese version of DLQI in Chinese patients with psoriasis.


Oncotarget | 2017

Untargeted serum metabonomics study of psoriasis vulgaris based on ultra-performance liquid chromatography coupled to mass spectrometry

Li Li; Chuanjian Lu; Ling Han; Jingwen Deng; Zehui He; Yuhong Yan; Zhongzhao Zhang

Psoriasis is a common, chronic, systemic inflammatory skin disease, the etiology and pathogenesis is unclear. An untargeted high-throughput metabonomics method based on liquid chromatography coupled to mass spectrometry was applied to study the serum metabolic changes in psoriasis vulgaris patients, and to discover serum potential biomarkers for identification, diagnosis and exploring pathogenesis of psoriasis. The serum metabolic profiles from 150 subjects (75 psoriasis patients and 75 healthy controls) were acquired, the raw spectrometric data were processed by multivariate statistical analysis, and 44 potential biomarkers were screened out and identified. The potential biomarkers were mainly involved in glycerophospholipid metabolism, sphingolipid metabolism, arachidonic acid metabolism, bile acid biosynthesis, indicated the pathogenesis of psoriasis may be related to the disturbed metabolic pathways.


BMJ Open | 2017

Oral Chinese herbal medicine for psoriasis vulgaris: protocol for a randomised, double-blind, double-dummy, multicentre clinical trial

Jingwen Deng; Danni Yao; Chuanjian Lu; Zehuai Wen; Yuhong Yan; Ziyang He; Huimei Wu; Hao Deng

Introduction Psoriasis vulgaris is a common skin disease that is characterised by persistent localised erythematous scaly plaques. Yinxieling is a Chinese herbal formula for psoriasis that has been used for more than 20 years in China. To facilitate application, PSORI-CM01 was developed based on the optimisation and simplification of Yinxieling tablets performed in a previous study and in clinical practice. However, the scientific evidence regarding whether PSORI-CM01 is more effective for psoriasis than the original Yinxieling remains insufficient. Therefore, we designed a randomised clinical trial to investigate the effect, safety and cost-effectiveness of PSORI-CM01 granules compared with those of Yinxieling tablets for the treatment of patients with psoriasis. Methods and analysis This ongoing study is a two-arm parallel, randomised, double-blind, double-dummy clinical trial. Five hundred and fifty-six participants with psoriasis will be recruited and then randomly allocated into two groups in a 1:1 ratio. Participants in PSORI-CM01 group will receive a 5.5 g granule of PSORI-CM01 two times daily and five placebo tablets three times daily for 12 weeks. The participants in the Yinxieling group will receive five Yinxieling tablets three times daily and a placebo granule two times daily for 12 weeks. The primary outcome is the reduction of the Psoriasis Area and Severity Index. The secondary outcomes include relapse rate, Visual Analogue Scale scores, body surface area and the Dermatology Life Quality Index. Cost-effectiveness analysis will be performed from a health and community care provider perspective. Ethics and dissemination This research protocol had been reviewed and approved by the institutional review boards of three trial centres (Guangdong Provincial Hospital of Chinese Medicine (B2014-026-01), Affiliated Hospital of Tianjin Chinese Medicine Academy (2014-KY-001) and Third Hospital of Hangzhou (B2014-026-01)). The findings will be disseminated to the public through conference presentations and open-access journals. Trial registration number Chinese Clinical Trial Registry (ChiCTR-TRC-14005185); Pre-results.


bioinformatics and biomedicine | 2013

Research on the psoriasis vulgaris syndrome differentiation standard of traditional Chinese medicine based on data mining technology

Xiuli Xie; Chuanjian Lu; Zhao Zeng; Zhangpeng Zeng; Yuhong Yan

Psoriasis is a common chronic skin disease of which the pathogenesis has not yet been fully elucidated. Traditional Chinese medicine (TCM) has effectiveness in treating this disease. Syndromes are the basic pathological units and key concepts of TCM theory, standardisation in TCM is significantly important for psoriasis diagnosis and treatment. Nevertheless, there are few documents concerning this issue. This study focused on psoriasis vulgaris, collected and analysed the literature in recent decades (1979-2011), applied data mining methods to analyse the characteristics of the main type symptoms, and formed psoriasis vulgaris syndrome diagnostic criteria.


Trials | 2016

Oral PSORI-CM01, a Chinese herbal formula, plus topical sequential therapy for moderate-to-severe psoriasis vulgaris: pilot study for a double-blind, randomized, placebo-controlled trial

Danni Yao; Chuanjian Lu; Zehuai Wen; Yuhong Yan; Mei-ling Xuan; Xiaoyan Li; Geng Li; Zehui He; Xiuli Xie; Jingwen Deng; Xinfeng Guo; Aihua Ou


Trials | 2014

Chinese medicine combined with calcipotriol betamethasone and calcipotriol ointment for Psoriasis vulgaris (CMCBCOP): study protocol for a randomized controlled trial

Zehuai Wen; Mei-ling Xuan; Yuhong Yan; Xiaoyan Li; Danni Yao; Geng Li; Xinfeng Guo; Aihua Ou; Chuanjian Lu


Complementary Therapies in Medicine | 2016

Terms referring to psoriasis vulgaris in the classical Chinese medicine literature: a systematic analysis

Claire Shuiqing Zhang; Brian H. May; Yuhong Yan; Jason Jingjie Yu; Danni Yao; Suyueh Chang; Anthony Lin Zhang; Xinfeng Guo; Chuanjian Lu; Charlie Changli Xue


Trials | 2016

A statistical analysis plan for the efficiency and safety of Chinese herbal medicine used concurrently with topical therapy for psoriasis vulgaris

Liming Lu; Mei-ling Xuan; Yuhong Yan; Geng Li; Li Zhou; Zehuai Wen; Chuanjian Lu


Archive | 2014

Interventions for chronic idiopathic urticaria excluding antihistamines (Protocol)

Jingwen Deng; Chuanjian Lu; Chi Cc; Ching-Chi Chi; Zehui He; Jingjie Yu; Xinfeng Guo; Guo Xf; Xue Ccl; Charlie Cl Xue; Anthony Lin Zhang; Yuhong Yan; Weifeng Zeng

Collaboration


Dive into the Yuhong Yan's collaboration.

Top Co-Authors

Avatar

Chuanjian Lu

Guangzhou University of Chinese Medicine

View shared research outputs
Top Co-Authors

Avatar

Jingwen Deng

Guangzhou University of Chinese Medicine

View shared research outputs
Top Co-Authors

Avatar

Xinfeng Guo

Guangzhou University of Chinese Medicine

View shared research outputs
Top Co-Authors

Avatar

Danni Yao

Guangzhou University of Chinese Medicine

View shared research outputs
Top Co-Authors

Avatar

Zehuai Wen

Guangzhou University of Chinese Medicine

View shared research outputs
Top Co-Authors

Avatar

Zehui He

Sun Yat-sen University

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Aihua Ou

Guangzhou University of Chinese Medicine

View shared research outputs
Top Co-Authors

Avatar

Jingjie Yu

Guangzhou University of Chinese Medicine

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge